Skip to main content
Premium Trial:

Request an Annual Quote

InterGenetics Readies New HQ, Lab for OncoVue Testing

NEW YORK, Sept. 7 (GenomeWeb News) - InterGenetics has completed construction on a new 11,000-square-foot headquarters and laboratory in Oklahoma City in preparation for what it expects to be high demand for its genetic-based OncoVue breast-cancer risk predictive test. The company anticipates will be available next month, the firm said today.

According to InterGenetics, the firm expects it will recieve federal certification to perform the testing under CLIA standards, and InterGenetics is projecting that 15,000 of the tests will be processed within the first 12 months of the lab's operation.

In addition, InterGenetics CEO and President Craig Shimasaki said the company had secured $8 million worth of financing this summer that will aid in launching the OncoVue service, which InterGenetics claims "can determine the lifetime and age-specific risk of developing breast cancer for all women..

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.